logo

For the Inventor, By the Inventor

Berlin, Germany

Noxxon Pharma Ag


USPTO Granted Patents = 31

% Expired Patents = 38.7



Trademarks = 2

Forward Citations = 120

Loading Chart...
Loading Chart...

33 inventors (with patents filed for the assignee):

goldMedal Sven Klussmann (28 out of 32 patents)

silverMedal Christian Maasch (23 out of 26 patents)

bronzeMedal Florian Jarosch (20 out of 22 patents)

4.  Klaus Buchner (19 out of 21 patents)

5.  Werner Purschke (19 out of 20 patents)

6.  Dirk Eulberg (18 out of 18 patents)

7.  Axel Vater (8 out of 12 patents)

8.  Nicole Dinse (8 out of 8 patents)

9.  Kai Hohlig (4 out of 7 patents)

10.  Dirk Zboralski (3 out of 6 patents)

11.  Steffen Helmling (3 out of 3 patents)

12.  Lucas Bethge (2 out of 12 patents)

13.  Simone Sell (2 out of 2 patents)

14.  Frank Schwobel (2 out of 2 patents)

15.  Bernd Eschgfäller (2 out of 2 patents)


Core Competencies:
Nucleic Acids
SDF-1 Binding
MCP-1 Binding
C5a Binding
Spiegelmers
Tumor-Infiltrating Leukocytes
Polyalkoxylation
Lipid Binding
Enzymatic Synthesis
Ghrelin Binding
CGRP Binding
Hepcidin Binding

31 patents:

1. 11459352 - Method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent (2022-10-04),
2. 11371045 - Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors (2022-06-28),
3. 10590424 - C5a binding nucleic acids (2020-03-17),
4. 10513536 - Methods for the preparation of a polyalkoxylated nucleic acid molecule (2019-12-24),
5. 10273480 - MCP-1 binding nucleic acids (2019-04-30),
6. 10093934 - SDF-1 binding nucleic acids and the use thereof in cancer treatment (2018-10-09),
7. 9988636 - SDF-1 binding nucleic acids and the use thereof (2018-06-05),
8. 9976145 - Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same (2018-05-22),
9. 9850471 - Enzymatic synthesis of L-nucleic acids (2017-12-26),
10. 9822369 - SDF-1 binding nucleic acids (2017-11-21),
11. 9670491 - MCP-1 binding nucleic acids (2017-06-06),
12. 9518265 - C5a binding nucleic acids (2016-12-13),
13. 9387221 - SDF-1 binding nucleic acids and the use thereof in cancer treatment (2016-07-12),
14. 9163243 - Nucleic acids specifically binding CGRP (2015-10-20),
15. 9074214 - Use of spiegelmers (2015-07-07),
Company Overview
Noxxon Pharma AG is a biopharmaceutical company based in Berlin, Germany, focused on the development of innovative therapies for cancer and other serious diseases. The company specializes in the design and manufacture of proprietary drug candidates that utilize its unique platform technology, which aims to enhance the efficacy of existing treatments. Noxxon's research emphasizes the potential of its compounds in targeting specific disease mechanisms, contributing to advancements in personalized medicine and improving patient outcomes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Noxxon Pharma Ag USPTO Patent Assignee Logo
31 Patents

#32 in D-1000 Berlin

#1,565 in Germany

#21,238 in the World

Berlin, DE
Berlin, Germany

Noxxon Pharma Ag

Forward Citations = 120

33 inventors:

goldMedal Sven Klussmann (28 out of 32 patents)

silverMedal Christian Maasch (23 out of 26 patents)

bronzeMedal Florian Jarosch (20 out of 22 patents)

4.  Klaus Buchner (19 out of 21 patents)

5.  Werner Purschke (19 out of 20 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Noxxon Pharma Ag. Retrieved from https://idiyas.com/company/noxxon-pharma-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…